Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111182

Cover Image

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111182

MEA Glioblastoma Multiforme Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 231 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Web Access (Single User License) - Read Only
USD 3500
Web Access (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The glioblastoma multiforme treatment market is projected to register a substantial CAGR of 8.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Middle East and Africa Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Egypt, Israel, UAE, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the glioblastoma multiforme treatment market are:

Increasing prevalence of the disease

High incidence in emerging markets.

Market Players:

Some of the major players operating in the market are:

F. Hoffmann-La Roche AG

Amgen Inc.

Merck & Co., Inc.

Pfizer Inc.

Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare)

ZEISS International

Amneal Pharmaceuticals LLC

Elekta

Sun Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd.

Eckert & Ziegler

Accord Healthcare

Angiochem

ANI Pharmaceuticals, Inc.

Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.)

AstraZeneca

Cantex Pharmaceuticals, Inc.

CELON LABS

Diffusion Pharmaceuticals Inc.

EnGeneIC

ERC.SA.

Genenta science

Jazz Pharmaceuticals, Inc.

Loxo Oncology (A Subsidiary of Eli Lilly)

Novartis AG

VBL THERAPEUTICS

Viatris Inc.

Zydus Pharmaceuticals, Inc.,

TABLE OF CONTENTS

1 INTRODUCTION 53

  • 1.1 OBJECTIVES OF THE STUDY 53
  • 1.2 MARKET DEFINITION 53
  • 1.3 OVERVIEW OF MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET 53
  • 1.4 LIMITATIONS 55
  • 1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

  • 2.1 MARKETS COVERED 59
  • 2.2 GEOGRAPHICAL SCOPE 60
  • 2.3 YEARS CONSIDERED FOR THE STUDY 61
  • 2.4 CURRENCY AND PRICING 61
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
  • 2.6 MULTIVARIATE MODELLING 65
  • 2.7 TYPE LIFELINE CURVE 65
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
  • 2.9 DBMR MARKET POSITION GRID 67
  • 2.10 MARKET END USER COVERAGE GRID 68
  • 2.11 VENDOR SHARE ANALYSIS 69
  • 2.12 SECONDARY SOURCES 70
  • 2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 75

  • 4.1 PESTEL 76
  • 4.2 PORTER'S FIVE FORCES MODEL 77

5 EPIDEMIOLOGY 78

6 PIPELINE ANALYSIS 80

7 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: REGULATORY SCENARIO 82

8 MARKET OVERVIEW 84

  • 8.1 DRIVERS 86
    • 8.1.1 GROWING PREVALENCE OF GLIOBLASTOMA MULTIFORME 86
    • 8.1.2 INCREASING RESEARCH AND DEVELOPMENT (R&D) 86
    • 8.1.3 PRESENCE OF A STRONG PIPELINE 87
    • 8.1.4 GROWING GERIATRIC POPULATION 88
  • 8.2 RESTRAINTS 89
    • 8.2.1 HIGH COST OF GLIOBLASTOMA MULTIFORME TREATMENT 89
    • 8.2.2 ADVERSE SIDE-EFFECTS OF GLIOBLASTOMA MULTIFORME TREATMENT 90
  • 8.3 OPPORTUNITIES 90
    • 8.3.1 INCREASING DRUG APPROVALS 90
    • 8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 91
    • 8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT 91
  • 8.4 CHALLENGES 92
    • 8.4.1 LACK OF NEW TREATMENT 92
    • 8.4.2 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS 92
    • 8.4.3 LACK OF EARLY DETECTION 93

9 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE 94

  • 9.1 OVERVIEW 95
  • 9.2 PRIMARY (DE NOVO) 98
  • 9.3 SECONDARY 98

10 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT 100

  • 10.1 OVERVIEW 101
  • 10.2 SURGERY 104
  • 10.3 RADIOTHERAPY 104
    • 10.3.1 BRACHYTHERAPY 105
    • 10.3.2 FRACTIONATED STEREOTACTIC RT (FSRT) 105
    • 10.3.3 CONFORMAL OR INTENSITY-MODULATED RT 105
    • 10.3.4 RADIOSURGERY 106
  • 10.4 MEDICATIONS 106
    • 10.4.1 TEMOZOLOMIDE 107
      • 10.4.1.1 ORAL 107
      • 10.4.1.1 INTRAVENOUS 107
    • 10.4.2 NITROSOUREAS DRUGS 107
      • 10.4.2.1 CARMUSTINE 108
        • 10.4.2.1.1 PARENTERAL 108
        • 10.4.2.1.2 IMPLANTABLE WAFERS 108
      • 10.4.2.2 LOMUSTINE 108
      • 10.4.2.3 NIMUSTINE 109
      • 10.4.2.4 FOTEMUSTINE 109
    • 10.4.3 TARGETED THERAPY 109
      • 10.4.3.1 BEVACIZUMAB 109
      • 10.4.3.2 OTHERS 109
    • 10.4.4 ANTI-EPILEPTICS 109
      • 10.4.4.1 LEVETIRACETAM 110
      • 10.4.4.2 PHENYTOIN 110
      • 10.4.4.3 CARBAMAZEPINE 110
    • 10.4.5 CORTICOSTEROIDS 110
      • 10.4.5.1 METHYLPREDNISOLONE 111
      • 10.4.5.2 PREDNISONE 111
      • 10.4.5.3 OTHERS 111

11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE 112

  • 11.1 OVERVIEW 113
  • 11.2 ADULT 116
    • 11.2.1 MALE 116
    • 11.2.2 FEMALE 117
  • 11.3 GERIATRIC 117
    • 11.3.1 MALE 118
    • 11.3.2 FEMALE 118
  • 11.4 CHILD 118

12 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE 120

  • 12.1 OVERVIEW 121
  • 12.2 GENERICS 124
  • 12.3 BRANDED 124

13 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 126

  • 13.1 OVERVIEW 127
  • 13.2 PARENTERAL 130
  • 13.3 ORAL 130
    • 13.3.1 CAPSULES 131
    • 13.3.2 TABLETS 131
    • 13.3.3 POWDERS 131
  • 13.4 OTHERS 131

14 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER 133

  • 14.1 OVERVIEW 134
  • 14.2 HOSPITAL 137
  • 14.3 CLINICS 137
  • 14.4 HOME HEALTHCARE 138
  • 14.5 OTHERS 139

15 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL 140

  • 15.1 OVERVIEW 141
  • 15.2 HOSPITAL PHARMACY 144
  • 15.3 RETAIL PHARMACY 144
  • 15.4 ONLINE PHARMACY 145
  • 15.5 OTHERS 145

16 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION 147

  • 16.1 MIDDLE EAST & AFRICA 148
    • 16.1.1 SOUTH AFRICA 158
    • 16.1.2 U.A.E. 162
    • 16.1.3 EGYPT 166
    • 16.1.4 ISRAEL 170
    • 16.1.5 REST OF MIDDLE EAST AND AFRICA 174

17 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE 175

  • 17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 175

18 SWOT ANALYSIS 176

19 COMPANY PROFILE 177

  • 19.1 F.HOFFMAN-LA ROCHE 177
    • 19.1.1 COMPANY SNAPSHOT 177
    • 19.1.2 REVENUE ANALYSIS 177
    • 19.1.3 COMPANY SHARE ANALYSIS 178
    • 19.1.4 PRODUCT PORTFOLIO 178
    • 19.1.5 RECENT DEVELOPMENT 178
  • 19.2 AMGEN INC. 179
    • 19.2.1 COMPANY SNAPSHOT 179
    • 19.2.2 REVENUE ANALYSIS 179
    • 19.2.3 COMPANY SHARE ANALYSIS 180
    • 19.2.4 PRODUCT PORTFOLIO 180
    • 19.2.5 RECENT DEVELOPMENTS 180
      • 19.2.5.1 PRODUCT APPROVAL 180
  • 19.3 MERCK & CO., INC 181
    • 19.3.1 COMPANY SNAPSHOT 181
    • 19.3.2 REVENUE ANALYSIS 181
    • 19.3.3 COMPANY SHARE ANALYSIS 182
    • 19.3.4 PRODUCT PORTFOLIO 182
    • 19.3.5 RECENT DEVELOPMENTS 182
      • 19.3.5.1 STRATETIC COLLABORATION 182
      • 19.3.5.2 EVENTS 183
  • 19.4 PFIZER INC. 184
    • 19.4.1 COMPANY SNAPSHOT 184
    • 19.4.2 REVENUE ANALYSIS 184
    • 19.4.3 COMPANY SHARE ANALYSIS 185
    • 19.4.4 PRODUCT PORTFOLIO 185
    • 19.4.5 RECENT DEVELOPMENT 185
      • 19.4.5.1 MERGER 185
  • 19.5 VARIAN MEDICAL SYSTEMS, INC. (A SUBSIDIARY OF SIEMENS HEALTHCARE) 186
    • 19.5.1 COMPANY SNAPSHOT 186
    • 19.5.2 REVENUE ANALYSIS 186
    • 19.5.3 COMPANY SHARE ANALYSIS 187
    • 19.5.4 PRODUCT PORTFOLIO 187
    • 19.5.5 RECENT DEVELOPMENT 187
      • 19.5.5.1 PARTNERSHIP 187
      • 19.5.5.2 ACQUISITION 188
  • 19.6 ZEISS INTERNATIONAL 189
    • 19.6.1 COMPANY SNAPSHOT 189
    • 19.6.2 REVENUE ANALYSIS 189
    • 19.6.3 PRODUCT PORTFOLIO 190
    • 19.6.4 RECENT DEVELOPMENTS 190
      • 19.6.4.1 PRODUCT EXPANSION 190
  • 19.7 AMNEAL PHARMACEUTICALS LLC 191
    • 19.7.1 COMPANY SNAPSHOT 191
    • 19.7.2 REVENUE ANALYSIS 191
    • 19.7.3 PRODUCT PORTFOLIO 192
    • 19.7.4 RECENT DEVELOPMENTS 192
      • 19.7.4.1 EVENT 192
      • 19.7.4.2 LAUNCH 192
      • 19.7.4.3 ACQUISITION 193
  • 19.8 ELEKTA 194
    • 19.8.1 COMPANY SNAPSHOT 194
    • 19.8.2 REVENUE ANALYSIS 194
    • 19.8.3 PRODUCT PORTFOLIO 195
    • 19.8.4 RECENT DEVELOPMENTS 195
      • 19.8.4.1 PARTNERSHIP 195
  • 19.9 SUN PHARMACEUTICAL INDUSTRIES LTD 196
    • 19.9.1 COMPANY SNAPSHOT 196
    • 19.9.2 REVENUE ANALYSIS 196
    • 19.9.3 PRODUCT PORTFOLIO 197
    • 19.9.4 RECENT DEVELOPMENT 197
      • 19.9.4.1 AGREEMENT 197
  • 19.10 TEVA PHARMACEUTICAL INDUSTRIES LTD 198
    • 19.10.1 COMPANY SNAPSHOT 198
    • 19.10.2 REVENUE ANALYSIS 198
    • 19.10.3 PRODUCT PORTFOLIO 199
    • 19.10.4 RECENT DEVELOPMENT 199
  • 19.11 ECKERT & ZIEGLER 200
    • 19.11.1 COMPANY SNAPSHOT 200
    • 19.11.2 REVENUE ANALYSIS 200
    • 19.11.3 PRODUCT PORTFOLIO 201
    • 19.11.4 RECENT DEVELOPMENT 201
  • 19.12 ACCORD HEALTHCARE 202
    • 19.12.1 COMPANY SNAPSHOT 202
    • 19.12.2 PRODUCT PORTFOLIO 202
    • 19.12.3 RECENT DEVELOPMENT 202
  • 19.13 ANGIOCHEM 203
    • 19.13.1 COMPANY SNAPSHOT 203
    • 19.13.2 PRODUCT PORTFOLIO 203
    • 19.13.3 RECENT DEVELOPMENT 203
      • 19.13.3.1 AGREMEENT 203
  • 19.14 ANI PHARMACEUTICALS, INC. 204
    • 19.14.1 COMPANY SNAPSHOT 204
    • 19.14.2 REVENUE ANALYSIS 204
    • 19.14.3 PRODUCT PORTFOLIO 205
    • 19.14.4 RECENT DEVELOPMENTS 205
      • 19.14.4.1 ACQUISITION 205
  • 19.15 ARBOR PHARMACEUTICALS, LLC. A SUBSIDIARY OF AZURITY PHARMACEUTICALS, INC. 206
    • 19.15.1 COMPANY SNAPSHOT 206
    • 19.15.2 PRODUCT PORTFOLIO 206
    • 19.15.3 RECENT DEVELOPMENT 206
      • 19.15.3.1 ACQUISITION 206
      • 19.15.3.2 PRODUCT APPROVAL 207
  • 19.16 ASTRAZENECA 208
    • 19.16.1 COMPANY SNAPSHOT 208
    • 19.16.2 REVENUE ANALYSIS 208
    • 19.16.3 PRODUCT PORTFOLIO 209
    • 19.16.4 RECENT DEVELOPMENT 209
      • 19.16.4.1 AGREEMENT 209
  • 19.17 CANTEX PHARMACEUTICALS, INC. 210
    • 19.17.1 COMPANY SNAPSHOT 210
    • 19.17.2 PRODUCT PORTFOLIO 210
    • 19.17.3 RECENT DEVELOPMENT 210
  • 19.18 CELON LABS 211
    • 19.18.1 COMPANY SNAPSHOT 211
    • 19.18.2 PRODUCT PORTFOLIO 211
    • 19.18.3 RECENT DEVELOPMENT 211
  • 19.19 DIFFUSION PHARMACEUTICAL 212
    • 19.19.1 COMPANY SNAPSHOT 212
    • 19.19.2 SERVICES PORTFOLIO 212
    • 19.19.3 RECENT DEVELOPMENT 212
  • 19.20 ERC.SA 213
    • 19.20.1 COMPANY SNAPSHOT 213
    • 19.20.2 PRODUCT PORTFOLIO 213
    • 19.20.3 RECENT DEVELOPMENT 213
      • 19.20.3.1 PIPELINE UPDATE 213
  • 19.21 ENGENEIC 214
    • 19.21.1 COMPANY SNAPSHOT 214
    • 19.21.2 PRODUCT PORTFOLIO 214
    • 19.21.3 RECENT DEVELOPMENTS 214
      • 19.21.3.1 AWARDS 215
  • 19.22 GENENTA SCIENCE 216
    • 19.22.1 COMPANY SNAPSHOT 216
    • 19.22.2 PRODUCT PORTFOLIO 216
    • 19.22.3 RECENT DEVELOPMENT 216
      • 19.22.3.1 EVENT 216
  • 19.23 JAZZ PHARMACEUTICALS, INC. 217
    • 19.23.1 COMPANY SNAPSHOT 217
    • 19.23.2 REVENUE ANALYSIS 217
    • 19.23.3 PRODUCT PORTFOLIO 218
    • 19.23.4 RECENT DEVELOPMENT 218

19..4.1 ACUISITION 218

  • 19.24 LOXO ONCOLOGY (A SUBSIDIARY OF ELI LILLY) 219
    • 19.24.1 COMPANY SNAPSHOT 219
    • 19.24.2 PRODUCT PORTFOLIO 219
    • 19.24.3 RECENT DEVELOPMENT 219
  • 19.25 NOVARTIS AG 220
    • 19.25.1 COMPANY SNAPSHOT 220
    • 19.25.2 REVENUE ANALYSIS 220
    • 19.25.3 PRODUCT PORTFOLIO 221
    • 19.25.4 RECENT DEVELOPMENT 221
  • 19.26 VBL THERAPEUTICS 222
    • 19.26.1 COMPANY SNAPSHOT 222
    • 19.26.2 PRODUCT PORTFOLIO 222
    • 19.26.3 RECENT DEVELOPMENT 222
      • 19.26.3.1 EVENT 222
      • 19.26.3.2 AWARD 223
  • 19.27 VIATRIS INC 224
    • 19.27.1 COMPANY SNAPSHOT 224
    • 19.27.2 REVENUE ANALYSIS 224
    • 19.27.3 PRODUCT PORTFOLIO 225
    • 19.27.4 RECENT DEVELOPMENT 225
      • 19.27.4.1 AGREEMENT 225

  • 19.28 ZYDUS PHARMACEUTICALS, INC. 226
    • 19.28.1 COMPANY SNAPSHOT 226
    • 19.28.2 PRODUCT PORTFOLIO 226
    • 19.28.3 RECENT DEVELOPMENTS 226

20 QUESTIONNAIRE 227

21 RELATED REPORTS 231

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET 49
  • TABLE 2 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 66
  • TABLE 3 MIDDLE EAST & AFRICA PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 4 MIDDLE EAST & AFRICA SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 68
  • TABLE 5 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 72
  • TABLE 6 MIDDLE EAST & AFRICA SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 73
  • TABLE 7 MIDDLE EAST & AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 74
  • TABLE 8 MIDDLE EAST & AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 74
  • TABLE 9 MIDDLE EAST & AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 75
  • TABLE 10 MIDDLE EAST & AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 76
  • TABLE 11 MIDDLE EAST & AFRICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 76
  • TABLE 12 MIDDLE EAST & AFRICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 77
  • TABLE 13 MIDDLE EAST & AFRICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 77
  • TABLE 14 MIDDLE EAST & AFRICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 78
  • TABLE 15 MIDDLE EAST & AFRICA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 79
  • TABLE 16 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 79
  • TABLE 17 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 84
  • TABLE 18 MIDDLE EAST & AFRICA ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 85
  • TABLE 19 MIDDLE EAST & AFRICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 85
  • TABLE 20 MIDDLE EAST & AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 86
  • TABLE 21 MIDDLE EAST & AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 87
  • TABLE 22 MIDDLE EAST & AFRICA CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 23 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 92
  • TABLE 24 MIDDLE EAST & AFRICA GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 93
  • TABLE 25 MIDDLE EAST & AFRICA BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 94
  • TABLE 26 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 98
  • TABLE 27 MIDDLE EAST & AFRICA PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 99
  • TABLE 28 MIDDLE EAST & AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 100
  • TABLE 29 MIDDLE EAST & AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 100
  • TABLE 30 MIDDLE EAST & AFRICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 101
  • TABLE 31 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 105
  • TABLE 32 MIDDLE EAST & AFRICA HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 33 MIDDLE EAST & AFRICA CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 34 MIDDLE EAST & AFRICA HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 35 MIDDLE EAST & AFRICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 36 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 112
  • TABLE 37 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 113
  • TABLE 38 MIDDLE EAST & AFRICA RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 114
  • TABLE 39 MIDDLE EAST & AFRICA ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 114
  • TABLE 40 MIDDLE EAST & AFRICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 115
  • TABLE 41 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 122
  • TABLE 42 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 122
  • TABLE 43 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 122
  • TABLE 44 MIDDLE EAST & AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 122
  • TABLE 45 MIDDLE EAST & AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 123
  • TABLE 46 MIDDLE EAST & AFRICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 123
  • TABLE 47 MIDDLE EAST & AFRICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 123
  • TABLE 48 MIDDLE EAST & AFRICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 123
  • TABLE 49 MIDDLE EAST & AFRICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 124
  • TABLE 50 MIDDLE EAST & AFRICA ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 124
  • TABLE 51 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 124
  • TABLE 52 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 53 MIDDLE EAST & AFRICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 54 MIDDLE EAST & AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 55 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 56 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 125
  • TABLE 57 MIDDLE EAST & AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 125
  • TABLE 58 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 125
  • TABLE 59 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 126
  • TABLE 60 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 127
  • TABLE 61 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 62 SOUTH AFRICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 63 SOUTH AFRICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 64 SOUTH AFRICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 128
  • TABLE 65 SOUTH AFRICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 128
  • TABLE 66 SOUTH AFRICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 128
  • TABLE 67 SOUTH AFRICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 128
  • TABLE 68 SOUTH AFRICA ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 128
  • TABLE 69 SOUTH AFRICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 129
  • TABLE 70 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 71 SOUTH AFRICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 72 SOUTH AFRICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 73 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 74 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 130
  • TABLE 75 SOUTH AFRICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 130
  • TABLE 76 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 130
  • TABLE 77 SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 130
  • TABLE 78 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 79 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 80 U.A.E. RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 81 U.A.E. MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 82 U.A.E. TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 83 U.A.E. NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 84 U.A.E. CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 85 U.A.E. TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 86 U.A.E. ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 87 U.A.E. CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 133
  • TABLE 88 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 89 U.A.E. ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 90 U.A.E. GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 91 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 92 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 134
  • TABLE 93 U.A.E. ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 134
  • TABLE 94 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 134
  • TABLE 95 U.A.E. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 134
  • TABLE 96 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
  • TABLE 97 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 98 EGYPT RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 99 EGYPT MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 100 EGYPT TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 101 EGYPT NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 102 EGYPT CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 103 EGYPT TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 104 EGYPT ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 105 EGYPT CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 137
  • TABLE 106 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 107 EGYPT ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 108 EGYPT GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 109 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 110 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 138
  • TABLE 111 EGYPT ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 138
  • TABLE 112 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 138
  • TABLE 113 EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 138
  • TABLE 114 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 115 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 116 ISRAEL RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 117 ISRAEL MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 139
  • TABLE 118 ISRAEL TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 119 ISRAEL NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 120 ISRAEL CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 121 ISRAEL TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 122 ISRAEL ANTI-EPILEPTIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 123 ISRAEL CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 141
  • TABLE 124 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 125 ISRAEL ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 126 ISRAEL GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 127 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 128 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 142
  • TABLE 129 ISRAEL ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 142
  • TABLE 130 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 142
  • TABLE 131 ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 142
  • TABLE 132 REST OF MIDDLE EAST AND AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 143

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 27
  • FIGURE 2 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION 30
  • FIGURE 3 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS 31
  • FIGURE 4 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 32
  • FIGURE 5 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 32
  • FIGURE 6 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING 33
  • FIGURE 7 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 34
  • FIGURE 8 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID 35
  • FIGURE 9 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID 36
  • FIGURE 10 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS 37
  • FIGURE 11 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 41
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 42
  • FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 43
  • FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029 43
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET 53
  • FIGURE 16 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021 63
  • FIGURE 17 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION) 64
  • FIGURE 18 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029) 64
  • FIGURE 19 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE 65
  • FIGURE 20 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021 69
  • FIGURE 21 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION) 70
  • FIGURE 22 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029) 70
  • FIGURE 23 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE 71
  • FIGURE 24 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021 81
  • FIGURE 25 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 82
  • FIGURE 26 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029) 82
  • FIGURE 27 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE 83
  • FIGURE 28 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021 89
  • FIGURE 29 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 90
  • FIGURE 30 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029) 90
  • FIGURE 31 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE 91
  • FIGURE 32 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021 95
  • FIGURE 33 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 96
  • FIGURE 34 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 96
  • FIGURE 35 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 97
  • FIGURE 36 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021 102
  • FIGURE 37 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION) 103
  • FIGURE 38 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029) 103
  • FIGURE 39 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE 104
  • FIGURE 40 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021 109
  • FIGURE 41 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 110
  • FIGURE 42 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 110
  • FIGURE 43 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 111
  • FIGURE 44 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 117
  • FIGURE 45 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 119
  • FIGURE 46 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 119
  • FIGURE 47 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 120
  • FIGURE 48 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022 & 2029) 120
  • FIGURE 49 MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 143
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!